Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu

Read the full paper here.
Find similar posts on Hemostasis Today.
-
Mar 6, 2026, 09:15Reza Bavarsad Shahripour: When the Ophthalmic Artery Tells the Story of the Carotid
-
Mar 6, 2026, 09:13Louise St. Germain Bannon: Advancing Thrombosis and Hemostasis Through a Global Community
-
Mar 6, 2026, 09:06Kathleen Freson: Protein C Deficiency as a Genetic Modifier of Severe Haemophilia A
-
Mar 5, 2026, 17:48Estelle Carminita։ What If the Origin of Platelet Dysfunction Starts in the Bone Marrow
-
Mar 5, 2026, 17:43Pierre Sabouret: The Best Antithrombotic Strategy in Patients with Atherosclerotic Stroke and AF
-
Mar 5, 2026, 17:37John Abraham։ The Role of Diagnostic Splenectomy in Unexplained Splenomegaly
-
Mar 5, 2026, 17:31Fayad Al-Haimus: Key Themes from the New 2026 AHA/ACC Guideline for Acute PE
-
Mar 5, 2026, 16:56From Chronic Pain with Every Step to Exercising Every Day – EHC
-
Mar 5, 2026, 15:51Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies